COMMUNIQUÉS West-GlobeNewswire

IBA SA : IBA - TRANSPARENCY NOTIFICATION

13/07/2017 - 09:25

IBA - TRANSPARENCY NOTIFICATION Louvain-la-Neuve, Belgium, July 11, 2017, 5.40 p.m. - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that [...]

Weifa ASA: Record second-quarter revenues driven by pain and cough & cold

13/07/2017 - 07:30

Oslo, 13 July 2017 Record second-quarter revenues of NOK 98.6 million (NOK 95.3 million) All-organic growth of 3.4% Second-quarter adjusted EBITDA of NOK 22.1 million (NOK 18.6 million) Adjusted EBITDA margin of 22.5% ( [...]

Vistin Pharma ASA : agreement to sell Opioids and CMO business - extended announcement

13/07/2017 - 07:30

Oslo, Norway, 13 July 2017 Reference is made to the stock exchange announcement on 11 July relating to the sale of Vistin Pharma ASA's ("Vistin Pharma" or "Company") opioids and tablet manufacturing business (CMO) ( [...]

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL

12/07/2017 - 23:20

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial A Biologics License Application (BLA) for this indication is under FDA priority review; if [...]

Sanofi: Availability of the Pre-quarterly Results Communication

12/07/2017 - 22:30

Availability of the Pre-quarterly Results Communication Paris, France - July 12, 2017 - Sanofi announced today that its Pre-Quarterly Results Communication document is available on the "Investors" page of the company's [...]

Sanofi: Pre-quarterly Results Communication

12/07/2017 - 22:30

Paris, July 12, 2017 Pre-quarterly Results Communication Sanofi (EURONEXT: SAN and NYSE: SNY) has compiled the following items for consideration to assist in the financial modeling of the company's Q2 2017 results. [...]

Sanofi : Mise en ligne du document «Pre-quarterly Results Communication »

12/07/2017 - 22:30

Mise en ligne du document «Pre-quarterly Results Communication » Paris, France - Le 12 juillet 2017 - Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « [...]

SPINEWAY : S1 2017 Bilan semestriel du contrat de liquidité

12/07/2017 - 20:51

Communiqué de Presse Ecully, 12 juillet 2017 BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE Au titre du contrat de liquidité confié par la société SPINEWAY à PORTZAMPARC Société de Bourse, à la date du 30 juin 2017 , les [...]

SPINEWAY:Liquidity contract half-yearly report

12/07/2017 - 20:51

Press release Ecully, 12 July 2017 LIQUIDITY CONTRACT HALF-YEARLY REPORT Regarding liquidity contract granted by SPINEWAY to PORTZAMPARC, the liquidity account held the following assets on 30th June 2017: 20 570 shares [...]

AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas

12/07/2017 - 17:56

Paris, 12 juillet 2017, 17h45 AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas et présentant une douleur [...]

AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

12/07/2017 - 17:56

Paris, 12 July 2017, 5.45pm AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 Recruitment target before possible resampling of [...]

AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas

12/07/2017 - 17:46

Paris, 12 juillet 2017, 17h45 AB Science annonce l'obtention d'un nouveau brevet européen protégeant jusqu'en 2033 l'utilisation du masitinib chez les patients atteints du cancer du pancréas et présentant une douleur [...]

AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

12/07/2017 - 17:46

Paris, 12 July 2017, 5.45pm AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients with pain until 2033 Recruitment target before possible resampling of [...]

FIT Biotech Oy: FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA)

12/07/2017 - 15:00

FIT Biotech Oy Company release 12 July, 2017 at 4:00 PM EET FIT Biotech Receives EUR 644,868 Payment from European HIV Vaccine Alliance (EHVA) FIT Biotech Oy ("Company") has received today a EUR 644,868 payment from its [...]

RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease

12/07/2017 - 14:00

The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn's disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of [...]

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

12/07/2017 - 09:00

FIT Biotech Oy Company release July 12, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Biocartis Group NV: Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements

12/07/2017 - 07:00

PRESS RELEASE: 12 July 2017, 07:00 CEST Biocartis' Idylla(TM) Instrument and Idylla(TM) Console exempt from US FDA 510(k) notification requirements Mechelen (Belgium), 12 July 2017 - Biocartis Group NV ('Biocartis' or [...]

VIFOR PHARMA ANNOUNCES THREE OUTCOMES TRIALS IN HEART FAILURE AND IRON DEFICIENCY

12/07/2017 - 06:59

PRESS RELEASE This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]

Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results

11/07/2017 - 22:05

Balance sheet strengthened with $120 million upfront payment and an $80 million share purchase from Incyte Corporation for global strategic research collaboration to discover and develop bispecific antibodies Based on [...]